GlassScriptPhysician profile
Alanda James
NPI 1598112583
$3,384.87
in general payments reported to CMS, 2019-2025
30 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $931 · 2022: $700 · 2023: $424 · 2024: $895 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Consulting Fee: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.22 |
| Consulting Fee | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $264.42 | 2022-2025 | Cervidil |
| Coherus Oncology, INC. | $230.39 | 2021 | |
| Axsome Therapeutics, INC. | $222.91 | 2025 | Auvelity |
| Janssen Biotech, INC. | $207.62 | 2022-2024 | Darzalex, Tecvayli |
| Abbvie INC. | $157.01 | 2021-2024 | |
| Gen-Probe Sales & Service, INC. | $141.38 | 2022 | |
| Emd Serono, INC. | $136.25 | 2024 | |
| Alexion Pharmaceuticals, INC. | $129.74 | 2024 | |
| Astellas Pharma Global Development | $129.60 | 2023 | Veozah |
| Genentech USA, INC. | $127.26 | 2021 | |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $124.99 | 2023 | Spravato |
| Jazz Pharmaceuticals INC. | $110.72 | 2021 | |
| Stryker Corporation | $109.44 | 2024 | Triton Canister System |
| Pacira Pharmaceuticals Incorporated | $107.01 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $96.89 | 2023 | Trogarzo |
| Celgene Corporation | $95.78 | 2021 | |
| Amgen INC. | $94.74 | 2021 | |
| Medtronic, INC. | $92.73 | 2025 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $90.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.45 | 2022 | |
| Avanir Pharmaceuticals, INC. | $87.24 | 2022 | |
| Puma Biotechnology, INC. | $82.09 | 2021 | |
| Inari Medical, INC. | $82.00 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $73.01 | 2023 | Wegovy |
| Pharmacyclics LLC, An Abbvie Company | $66.74 | 2021 | |
| Dendreon Pharmaceuticals LLC | $39.74 | 2021 | |
| Mayne Pharma Commercial LLC | $35.72 | 2025 | |
| Abbott Laboratories | $27.39 | 2022 | |
| Organon LLC | $7.31 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alanda James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.